Enfortumab vedotin is not traditional chemotherapy, but it does contain a chemotherapy component. It belongs to a newer class of cancer drugs called antibody-drug conjugates (ADCs), which pair a targeted antibody with a potent cell-killing agent. The distinction matters because ADCs work differently from standard chemotherapy, delivering their toxic payload more precisely to cancer cells rather than flooding the entire body.
How ADCs Differ From Standard Chemotherapy
Traditional chemotherapy circulates through your bloodstream and attacks any rapidly dividing cell it encounters. That’s why it causes widespread side effects like hair loss, nausea, and drops in blood cell counts. It kills cancer cells effectively, but it damages plenty of healthy tissue along the way.
Antibody-drug conjugates take a different approach. They consist of three parts: a monoclonal antibody that recognizes a specific protein on cancer cells, a chemical linker, and a cytotoxic (cell-killing) drug. The antibody acts like a guided missile, locking onto cancer cells and delivering the toxic drug directly inside them. This substantially reduces the damage to healthy cells compared to conventional chemotherapy, though it doesn’t eliminate side effects entirely.
Enfortumab vedotin targets a protein called Nectin-4, which sits on the surface of urothelial (bladder) cancer cells. Once the antibody binds to Nectin-4, the entire complex gets pulled inside the cell. There, the chemical linker breaks apart and releases a drug called MMAE, which disrupts the internal scaffolding the cell needs to divide. The cancer cell dies from the inside. Because Nectin-4 is far more abundant on cancer cells than on most healthy tissue, the drug concentrates where it’s needed most.
What Enfortumab Vedotin Treats
Enfortumab vedotin (brand name Padcev) is FDA-approved for adults with locally advanced or metastatic urothelial cancer. “Locally advanced” means the cancer has spread beyond the bladder into nearby tissue, and “metastatic” means it has reached distant parts of the body. It’s used both as a first-line treatment in combination with pembrolizumab (an immunotherapy drug) and in later settings after other treatments have stopped working.
The results from combining enfortumab vedotin with pembrolizumab have been striking. In the large EV-302 trial, patients receiving the combination lived a median of 33.8 months, compared to 15.9 months for patients on traditional chemotherapy. That’s more than double the survival time, with a 49% reduction in the risk of death. These results have made the combination a new standard of care for advanced bladder cancer.
What Treatment Looks Like
Enfortumab vedotin is given as a 30-minute intravenous infusion on days 1, 8, and 15 of a 28-day cycle. That means three infusion visits over three weeks, followed by a week off before the cycle repeats. Treatment continues as long as the cancer responds and side effects remain manageable. When combined with pembrolizumab, both drugs are given on the same day, with enfortumab vedotin administered first.
Side Effects to Expect
Because enfortumab vedotin delivers a chemotherapy drug (MMAE) inside cancer cells, it still causes side effects, though the profile looks different from traditional chemotherapy. The most common issues involve the skin, nerves, and blood sugar.
Skin Reactions
Skin problems are one of the hallmark side effects. Most are mild to moderate: rashes, dry skin, and itching. In a retrospective review, roughly 1% of patients developed severe skin reactions initially suspected to be Stevens-Johnson syndrome, though further evaluation pointed to alternative diagnoses. When skin toxicity does occur, it’s typically managed with topical or oral steroids, antihistamines, and moisturizers. In some cases, treatment may be paused, the dose adjusted, or the drug discontinued depending on severity.
Nerve Damage
Peripheral neuropathy, a tingling, numbness, or pain in the hands and feet, is the most frequent significant side effect. Between 50% and 65% of patients experience some degree of neuropathy, depending on whether they’re receiving enfortumab vedotin alone or in combination. Most cases are mild to moderate, but 3% to 8% of patients develop severe neuropathy. For mild cases, treatment continues at the same dose. If symptoms reach a moderate level and recur, the dose is reduced. Severe neuropathy means stopping the drug permanently, because nerve damage from MMAE can be slow to reverse.
Blood Sugar Spikes
About 10% of patients experience elevated blood sugar at some point during treatment, and 6% develop high-grade hyperglycemia requiring intervention. This can happen even in people without a history of diabetes. Regular blood sugar monitoring during treatment helps catch this early.
Why the Classification Matters
Whether you consider enfortumab vedotin “chemotherapy” depends on how broadly you define the term. It carries a traditional chemotherapy drug as its payload, so it’s not entirely separate from chemotherapy. But the delivery system is fundamentally different. The antibody targeting means less collateral damage to healthy cells, a different side effect profile, and in the case of bladder cancer, significantly better outcomes than conventional chemotherapy alone.
If you’re being offered enfortumab vedotin and wondering whether you’ll experience the classic chemotherapy side effects like severe nausea, hair loss, and immune suppression, the answer is that this drug has its own distinct set of challenges. Neuropathy and skin reactions take center stage rather than the bone marrow suppression and GI distress that define older chemotherapy regimens. It’s a targeted therapy that happens to use a chemotherapy molecule as its weapon, delivered with far more precision than an IV drip of chemotherapy alone could achieve.